Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
November 9, 2023
Earnings Call Speaker Segments
Jennifer Good
executiveGood afternoon, everyone, and thanks for being here for our update on the third quarter and the business. With me on the line are two colleagues: Lisa Delfini, who serves as Trevi's Chief Financial Officer, and David Clark, Trevi's Chief Medical Officer. Lisa and I will deliver some prepared remarks, and after that we'll take your questions. Our clinical development plans for Haduvio have kept moving forward across both chronic cough indications — idiopathic pulmonary fibrosis and refractory chronic cough — plus the human abuse potential study. Let me give you a quick update on each program. First up is the phase 2a refractory chronic cough study, which we started not long ago; we're calling it the RIVER study. On this call, refractory chronic cough, or RCC, affects up to one in ten adults. Doctors define it as a cough lasting more than eight weeks, either after treatment of an underlying condition or when no cough-related conditions can be identified. The condition stems from an overactive cough reflex involving nerves in the central and peripheral systems, and it weighs heavily on patients in physical, psychological, and social terms. Among those with high or moderate cough levels, 72% report that their cough remains uncontrolled. As of now, the U.S., E.U., and U.K. have no approved RCC therapies. Haduvio's distinguishing feature in chronic cough is how it works — targeting both the brain centrally and the lungs peripherally. Our belief is that Haduvio's central and peripheral mechanism could help more patients than mechanisms that act only peripherally, such as the P2X3s, and might deliver a stronger response and greater cough reduction. Looking at the competitive landscape in RCC, several other mechanisms have been tested with limited success. Even P2X3 inhibitors show mixed results, though two P2X3 therapies are in late stages — one under FDA review and another in Phase III trials. Importantly, however, both compounds demonstrated non-statistically significant effects in RCC patients whose cough frequency is moderate, at 10 to 19 coughs per hour. Drawing on what we learned in our IPF cough study plus how this drug acts, our belief is that Haduvio could be effective at both moderate and high cough frequencies. When you look at how RCC patients are spread out, roughly 44% fall into the moderate cough frequency group, whereas only 29% are in the high frequency group. So Haduvio has the potential to reach close to three-quarters of the RCC market, compared with P2X3s, which may only help fewer than one-third of it. As for RIVER, it follows the same phase 2a crossover format used across every cough trial: a two-period, randomized, double-blind, placebo-controlled crossover study that measures cough reduction in about 60 participants. Participants in the study will be assigned randomly, in a 1:1 ratio, split between two groups based on how often they cough: those who cough moderately, meaning 10 to 19 times each hour, and those who cough frequently, defined as 20 or more coughs per hour. Each period of treatment will last 21 days, and between those periods there will be a 21-day washout. For people taking Haduvio, the dose taken twice daily will be increased step by step on a weekly basis, starting at 27 milligrams and reaching 108 milligrams by the end of the dosing period. Regarding the main measure of efficacy, the focus is on how much the 24-hour cough frequency changes relatively by day 21, calculated from the baseline of the treatment period, with Haduvio compared to placebo, and this is done through an objective cough monitor. This trial will also look at secondary endpoints, including things such as patient-reported outcome measures related to cough and quality of life. We're pleased that this study is now underway, and we anticipate reporting top-line data during the second half of next year. Now, a brief update on our lead program, which is in idiopathic pulmonary fibrosis, or IPF, chronic cough. IPF is a severe disease that occurs at the end of life. About 85% of patients who have IPF report chronic cough, and it brings physical, psychological, and social effects comparable to those of RCC, and it might also be a risk factor that contributes to IPF progression. When someone coughs persistently, their lungs get hurt again and again, developing tiny tears and possibly inflammation, and that can lead to poorer health results for patients, including more hospital stays for respiratory reasons, death, or the need for a transplant. Because no treatments have won approval as of now for chronic cough and IPF, there's an urgent demand among patients and providers for new therapies; in this upcoming stage of development within our IPF chronic cough program, two studies are being planned to run side by side. The initial one is a Phase 2b dose-ranging trial with four arms that examines three active doses of Haduvio along with placebo; we intend to conduct a 6-week trial involving roughly 160 subjects. We intend to conduct this research in several nations and locations, which should allow us to finish enrolling participants promptly. Our conversations with regulators are still proceeding according to plan, and we have already gotten the go-ahead in a few of the countries where we intend to operate. We anticipate launching this trial during Q4 of 2023, and once we make the trial public, we will provide top-line guidance. At the same time, we are preparing a phase 1b study of respiratory physiology involving IPF patients whose disease severity varies. The purpose of this study is to establish whether we observe any subgroups experiencing clinically meaningful effects on respiratory depression. It will assist in specifying the patient population for our pivotal program and, in the end, the label. Our plan is to kick off that trial during Q1 of 2024. And then, on the human abuse potential study — something we need for the NDA submission — we managed to get moving forward again. As you'll remember, two obstacles stood in our way. One involved securing the FDA's blessing on the IV butorphanol dosage we intend to use during the likability phase. That approval came through from the agency over the course of the quarter. The other obstacle was lining up a supply of IV butorphanol, which comes from the lone supplier here in the U.S., and we got that done as well. The final portion of the HAP study employs a five-way crossover design that is randomized, double-blind, and controlled by both active and placebo comparators. Its aim is to determine the abuse potential of oral nalbuphine at three different doses relative to a selected butorphanol dose and placebo. The main goal is assessing how much nalbuphine is liked versus both placebo and butorphanol, with a drug-liking VAS scale acting as the primary endpoint. This trial's dosing is expected to begin during the first quarter of 2024, and we expect to have data in the second half of 2024. So as you're able to tell, this is a packed stretch on the clinical side for us, with those four trials now getting underway, and we're eager to run all of them and share what they show. At this point I'll pass it along to Lisa so she can walk through the numbers, and after that we'll take whatever questions you have.
Lisa Delfini
executiveAppreciate that, Jennifer, and hello to everybody this afternoon. You'll find the complete financial results covering the 3 months that wrapped up on September 30, 2023, in the press release we put out before this call began, along with our 10-Q, submitted to the SEC earlier today once trading had closed. Looking at Q3 2023, our net loss came in at $7.7 million, whereas during the comparable quarter of 2022 the net loss stood at $8.3 million. Spending on R&D reached $6.3 million across the third quarter of 2023, up from $5.8 million during that same quarter in 2022. That rise stemmed mainly from startup costs and consultant services tied to our chronic cough programs, plus higher personnel-related expenses. Partly counterbalancing those higher costs was a reduction in clinical development expenses connected to our finished phase 2b/3 PRISM and phase 2 CANAL trials, together with fewer purchases of clinical trial supplies. G&A costs amounted to $2.7 million in the third quarter of 2023, basically level with the $2.6 million recorded in the comparable stretch of 2022. What helped offset these higher expenses was growth in other income net, which reached $1.3 million during the third quarter of 2023, versus $100,000 in that same period of 2022. That shift came largely from greater interest income and lower interest expense following the payoff of the SVB term loan back in May 2023. On September 30, 2023, cash, cash equivalents, and marketable securities came to a total of $88.9 million, which compares with $120.5 million on December 31, 2022. We anticipate cash burn will step up somewhat across the coming several quarters while we run the trials Jennifer walked through today. Our guidance on cash runway — that we'll hold cash, cash equivalents, and marketable securities into 2026 — stays the same, and we believe it covers the funding of every trial Jennifer just described, leaving us solid cash runway following the final readout. That wraps up our prepared remarks, so I'll hand the call back to the operator now for Q&A.
Annabel Samimy
analystHello, and thank you for allowing me to ask. First, regarding the RCC study, what would you consider a normal amount of time for RCC to ramp up? How fierce is the competition for enrollment and within the development space, apart from the studies you just referenced? And I assume the same applies to IPF. While you await the launch of those studies, are you noticing any rival development efforts that could draw patients away from the studies and consequently cause enrollment to decelerate?
Jennifer Good
executiveThank you, Annabel. Since he is spearheading this effort, I will have David respond to that.
David Clark
executiveThanks so much, Jennifer. That's a key thing to ask about. Now, regarding how the RIVER trial is building up enrollment among RCC patients, we remain on schedule to have every one of the 14 planned sites active and running by the beginning of the first quarter. In fact, a good portion of those sites should be brought online by the close of the fourth quarter. The difficulties here: this is a modest-sized trial, just 60 patients, and we've been told by numerous PIs — quite a few of whom are currently engaged in other phase 3 RCC programs — that they definitely don't expect any trouble from competing with other RCC trials that are underway. A key element in that, which we've already made public, is that enrollment will use a 1:1 enrichment approach. That means at least half of the participants will be at 20 or more coughs per hour, while the other half will fall into the 10 to 19 range. So I believe that's one aspect that will support our ability to recruit for this trial. As a result, we don't foresee any issues on that front. Now then, does that address what you were asking about RCC before I continue?
Jennifer Good
executiveYes.
David Clark
executive-to the CORAL study?
Jennifer Good
executiveCorrect, that's right.
David Clark
executiveThen regarding the CORAL study, Annabel, could you go over that once more?
Jennifer Good
executiveShe wanted the same question, basically. Yeah.
David Clark
executiveOkay, regarding the CORAL trial, specifically the phase 2b portion involving IPF cough patients, our plan is to have most of the sites, the study centers, operational by the close of the first quarter. As previously stated, we'll kick off that trial soon, during Q4, yet with the bulk of locations up and running in Q1. From our conversations with numerous investigators involved in this trial, their feedback indicates that an IPF cough study typically presents a more favorable recruitment situation compared to running a disease-modifying program study for IPF. That's the expectation those investigators have for this particular study. To address your question directly, at this moment we do not anticipate major difficulties relative to other disease-modifying programs. If anything, we expect enrollment to exceed what those disease-modifying programs achieve.
Jennifer Good
executiveYes, and Annabel, let me just jump in here. I believe we've taken a very careful approach, since in earlier times we faced challenges with conditions that are hard to recruit for while still having a large number of sites. For IPF, we have roughly 60 sites aiming to enroll 160 patients, distributed across 10 countries. So my hope is that we have some solid capability supporting us to complete enrollment promptly.
Annabel Samimy
analystAll right, excellent. And could I just pose one more question regarding the PN program? We observed the safety data from the OLE, along with the remark that patients went on experiencing benefit on the WI-NRS score. Is there some magnitude you're able to provide to us on that, and do placebos have any possibility of crossing over in this trial? I can't recall whether that was among the components.
Jennifer Good
executiveYes.
Annabel Samimy
analystCould you tell us if there's any evidence of healing?
Jennifer Good
executiveRight, that small efficacy remark was meant as a hint. To answer you, yes — once the double-blind phase wrapped up, every participant moved over to active drug. That gave the placebo patients an opportunity to enter the study. At an upcoming conference, we intend to release the efficacy results related to this, and those will include data on skin healing. We have photographs, we have quality of life information, and as you can probably guess, when itching steadily declines across 12 months and patients remain on treatment for that long, the remaining endpoints, just like you observed in our double-blind trial, generally track along. However, we chose not to reveal that at this particular meeting, since we'd like to present it at a later one.
Annabel Samimy
analystAll right. And at this point, are you nearing an end-of-phase 2 meeting with the FDA?
Jennifer Good
executiveAs you've heard, things have been extremely busy for us, so I'd say that end-of-phase 2 meeting has been delayed somewhat — we intend to make that request during the first quarter, though we want to be certain a complete briefing document is prepared before we submit it, and that will actually also help address questions we might have, including ones tied to our cough program, since the molecule underneath is identical. So we expect to ask for a meeting in the first quarter, and from that point it takes about 70 days to secure one.
Annabel Samimy
analystOkay, great. Thank you.
Jennifer Good
executiveYeah. Thank you, Annabel.
Rohan Mathur
analystHi, all. Appreciate the update. This is on behalf of Lee Gershell. I have just a couple of questions. Given that Haduvio is moving forward in IPF chronic cough, how ought we to view the place Haduvio will occupy within the treatment regimen for IPF patients? And also, might you remind us whether any distinctions exist between the outcomes seen in moderate as opposed to severe cough in the CANAL trial?
Jennifer Good
executiveMm-hmm.
Rohan Mathur
analystAssuming that's the case, would these data points tend to show more of an advantage in moderate cough and severe cough, as well as in refractory chronic cough? Thank you.
Jennifer Good
executiveYeah. So I'll handle the first part. David, would you like to speak to the second part?
David Clark
executiveAbsolutely.
Jennifer Good
executiveThat makes sense. The way this gets dosed is actually pretty fascinating. I listened in on quite a few calls. Last summer, we conducted extensive research not just with people who have the condition, but with physicians treating them and those paying for care, all focused on precisely that issue. And, as you probably know, the antifibrotic medications are tough on those taking them. Many stop treatment sooner than they should, largely because of gastrointestinal adverse effects. What we also kept hearing is that someone on these drugs cannot perceive that their disease is advancing more slowly. In other words, research shows these drugs do prolong survival, yet patients still get worse over time. It's genuinely difficult for someone to notice that their rate of decline has been reduced. A point that came up repeatedly from the doctors running studies is that since the results in our trial were so striking in what is truly a hard-to-treat element of this condition, many of these clinicians would likely begin by putting patients on our product first, achieve a positive outcome—meaning those individuals feel improved and are coughing less—and afterward transition them. Their thinking was that this approach might raise the odds of successfully keeping people compliant with the antifibrotic. In essence, the message we received is that coughing shows up in this illness right from the start; it persists through every stage until the very end; and it was viewed as something to be deployed right away and maintained for the entire duration of the illness. I'll turn it over to David to discuss the cough measurements and our reasoning for believing it could be effective across both moderate and severe cases.
David Clark
executiveGlad to cover that. In the CANAL study, among the IPF cough patients, our post hoc analyses essentially examined whether cough frequency at baseline influences the efficacy signal. No relationship emerged. Thus, subjects whose baseline cough frequencies were lower showed an efficacy signal identical to those with higher baseline cough frequencies. That served as one rationale, while we were considering the enrichment strategy just disclosed for the RCC RIVER study, for choosing one-to-one enrichment, allowing us in essence to evaluate equally both the moderate cough frequency group, 10 to 19, and the high cough frequency group that the P2X3 programs target. We truly want a solid assessment; that absence of any baseline cough frequency to efficacy effect in CANAL, in our view, supports this approach.
Jennifer Good
executiveOur thinking is that since this drug acts centrally at the brain stem — the area that mediates both coughing and breathing — it truly ought to be effective across cough counts, you know, provided you reach some minimum level at which the variance isn't so large.
Rohan Mathur
analystThanks so much.
Jennifer Good
executiveThank you, Rohan.
Sean Kim
analystYes, hello, and thanks for taking my questions. My first one concerns the RCC trial. Since you're stratifying patients into moderate and severe groups, I'm curious about what the statistical plan might look like for each of those two groups. Specifically, will you be looking for statistical significance separately in the moderate group and in the severe group, as well as in the combined population? And apart from statistical significance, what level of reduction do you consider clinically meaningful, particularly in the moderate group? Thank you.
Jennifer Good
executiveYes. David?
David Clark
executiveThanks for asking that. In the RIVER study, we're looking at an N of 60, and we've powered it for a 45% treatment effect with Nalbuphine. That's a 25% effect on top of the placebo effect we anticipate — we've assumed 20% in that trial. That applies to the total population of 60 subjects. We believe that's suitably conservative, or obviously, what we observed was a separation from placebo much bigger than 25%; it was twice that—
Jennifer Good
executiveMm-hmm.
David Clark
executiveWithin the CANAL study, which, as you're aware, involved the IPF population. Therefore, our approach has been cautious, we believe. The implication is this: should the effect size we observe exceed 25% compared with placebo, then we would in fact possess 80% power across both subgroups. Consequently, if we surpass our cautious assumption of a 25% effect size versus placebo, we would have adequate power in each of the two groups, with roughly 30 subjects apiece. Is that an adequate answer to what you asked?
Sean Kim
analystYeah, that's true.
Jennifer Good
executiveDavid, he brought up clinical meaningfulness too. You know, how did we define what counts as clinical meaningfulness?
David Clark
executiveRight, and that basically establishes the fact that, as you're aware, a range of 20% to 30% is what most experts consider to be clinically meaningful when you're examining reductions of that kind in cough frequency. And that was among the reasons we chose this 20 — you know, the capability to power the 60 subjects with a 20 to detect an effect size of 25%, since that is clinically relevant for patients, or at least that is what experts in this area believe.
Sean Kim
analystAlright, that's excellent. I really appreciate it.
Jennifer Good
executiveThanks, Sean.
Serge Belanger
analystHello, and good afternoon. I appreciate you taking my questions. I've got two, and I suppose the first concerns the cough program. Could you perhaps discuss how the pathology differs between IPF cough and refractory chronic cough, and do you believe Haduvio's mechanism of action would work better in one of those diseases versus the other? Then, regarding the PN program, I'm just wondering whether any partnering conversations have taken place, and how would you characterize the interest level in that program? Thank you.
Jennifer Good
executiveDavid, why don't you handle the first one? I'll take the second one.
David Clark
executiveRight, it's a genuinely crucial question. Cough hypersensitivity acts as a major underlying force in both IPF and refractory chronic cough, as you're aware. So there's an overlap regarding what's behind both of these conditions, even though the pathophysiological initiation differs between the two, yet it produces the same kind of degree of cough hypersensitivity... I mean, our primary distinguishing element, as Jennifer mentioned in her presentation that you've heard from us previously, is what matters here. So we have peripheral activity, which is good; we also have central activity, which sets us apart. And essentially, it's that activity suppressing medullary, so b-a brain, basal cough reflex center and the cerebral, the higher level cerebral control of it. That's the primary distinction, so essentially, we believe that central activity and its capacity to be independent of whatever the triggering mechanism is will drive effects in both of these indications and other cough indications.
Jennifer Good
executiveThanks, Serge, for asking about PN partnering. Yes, we're still in contact with interested parties. Our colleague Farrell was at BIO-Europe this week, carrying on those conversations. So we have a clear picture of where the interest is and who's interested. Like we've consistently said, we'd like to finish the FDA meeting, get clarity on the path ahead and what remains, and at that point we'll decide whether or not to license the drug. So yes, interest remains strong.
Serge Belanger
analystThank you.
Jennifer Good
executiveThank you.
Mayank Mamtani
analystHello, everyone, and thanks for fielding my question. I found the remarks about the RCC landscape quite useful. What I wanted to know is what you'll be watching for when the FDA Ad comm takes place later in the year, regarding one of those P2X3 inhibitors you brought up. Then my second item concerned the IND filing — could you give us a refresher on where things stand in that process?
Jennifer Good
executiveSure. That Ad comm question is a good one, and David, feel free to jump in with anything extra. I plan to tune in for the entire session. It should be quite informative to see what the FDA concentrates on, or how they approach, Gefapixant. As you're aware, the placebo-adjusted change was modest, though statistical significance was achieved. They had to go back and perform additional work; because of that, my expectation is that the drug probably ends up approved. Merck is clearly devoting substantial resources toward preparing for launch, but I believe we'll all be watching simply to understand what the stance is and how it's perceived. David, I'm not sure whether there's anything further on the regulatory side that you're watching for?
David Clark
executiveNot really. In the same vein as your point, well, that's just my own take from hearing many specialists in this area — I definitely agree with your perspective. I'm hoping they get the green light—
Jennifer Good
executiveMm-hmm.
David Clark
executiveI believe it comes down to the medical need that exists in this area.
Jennifer Good
executiveYeah.
David Clark
executiveYou know?
Jennifer Good
executiveThat's correct. IND — do you want to handle that question? What's the status on opening an IND?
David Clark
executiveRegarding the respiratory physiology study, the IND is moving forward. Therefore, an announcement about it, along with its timing, should come shortly. That said, we remain on schedule to have it submitted before long.
Mayank Mamtani
analystUnderstood. Then perhaps just a single brief question about runway — could you make clear whether that figure presumes any extra spending on CN, or any money coming in that might result from a possible partnership conversation?
Jennifer Good
executiveNo — the runway figure is based on the cash we already hold, so no, we're not assuming any further cash coming in.
Mayank Mamtani
analystAnd, uh-
Jennifer Good
executiveOr in flow.
Mayank Mamtani
analystAh, got it. Alright, I appreciate that clarification. Thanks for letting me ask.
Jennifer Good
executiveSure. Thanks, Mayank.
Jennifer Good
executiveEveryone, we appreciate you joining us on today's call. Next week, we'll be at the Stifel Conference, and we're hoping some of you will be able to make it. Thanks.
Operator
operatorThis call is officially over. We appreciate your participation in today's presentation. You're welcome to leave the line now.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.